Jiang Jie, Nan Fang-Fang, Yang Xing-Sheng, Zhang You-Zhong, Wang Bo, Kong Bei-Hua
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua Fu Chan Ke Za Zhi. 2007 Sep;42(9):595-9.
To evaluate the feasibility and effectiveness of combination chemotherapy with etoposide and cisplatin (EP) regimen on the patients with high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia (GTN).
Thirty-nine patients with gestational trophoblastic tumors were analyzed retrospectively, 25 of 39 patients were of high-risk, 9 patients were chemorefractory and 5 patients were recurrent. All 39 patients were administrated with EP regimen, and 10 patients were assisted with surgery. All the patients were followed up. Clinical response, toxicity, the occurrence of secondary tumors of all patients, and the fertility of 30 patients whose fertility function was preserved were investigated.
Thirty-nine GTN patients underwent a total of 221 cycles of the EP regimen. The average number of courses for each patient was 5.7. The total complete remission rate of the regimen was 74% (29/39). Twenty-five patients with high-risk GTN received a total of 139 cycles and the average number of courses was 5.6. Nineteen patients achieved complete remission and 6 patients showed drug-resistant. The complete remission rate of the high-risk group was 76% (19/25). Nine patients with chemorefractory GTN obtained a total of 55 cycles and the average number of courses was 6.1. Six patients achieved complete remission and 3 patients showed drug-resistant again. The complete remission rate of the chemorefractory group was 6/9. Five patients with recurrent GTN received 27 cycles and the average number of courses was 5.4. Four patients achieved complete remission, 1 patient showed drug-resistance and died. Bone marrow toxicity, gastrointestinal reaction and alopecia were the main side effects of the EP regimen, but the bone marrow toxicity was slight and no grade IV side effect occurred. No fatal effect was found. Eight of 30 patients whose fertility fuction was preserved had become pregnant after recovery, with a total of 8 pregnancies. Among them, 2 were terminated by induced abortion, and 6 underwent normal term delivery and gained 6 infants who had no congenital malformation. All the 6 children had normal growth and development after childbirth. None of the women developed secondary tumors.
The EP regimen is effective and safe for the treatment of high-risk, chemorefractory and recurrent GTN.
评估依托泊苷和顺铂(EP)联合化疗方案治疗高危、化疗耐药及复发性妊娠滋养细胞肿瘤(GTN)患者的可行性和有效性。
回顾性分析39例妊娠滋养细胞肿瘤患者,其中高危患者25例,化疗耐药患者9例,复发患者5例。39例患者均接受EP方案化疗,10例患者辅助手术治疗。对所有患者进行随访,调查患者的临床反应、毒性反应、继发肿瘤发生情况以及30例保留生育功能患者的生育情况。
39例GTN患者共接受221周期EP方案化疗,平均每位患者化疗疗程为5.7个。该方案总完全缓解率为74%(29/39)。25例高危GTN患者共接受139周期化疗,平均疗程为5.6个。19例患者达到完全缓解,6例患者耐药。高危组完全缓解率为76%(19/25)。9例化疗耐药GTN患者共接受55周期化疗,平均疗程为6.1个。6例患者达到完全缓解,3例患者再次耐药。化疗耐药组完全缓解率为6/9。5例复发性GTN患者接受27周期化疗,平均疗程为5.4个。4例患者达到完全缓解,1例患者耐药死亡。骨髓毒性、胃肠道反应和脱发是EP方案的主要副作用,但骨髓毒性较轻,未出现Ⅳ级副作用。未发现致命性影响。30例保留生育功能的患者中,8例康复后怀孕,共妊娠8次。其中,2例人工流产终止妊娠,6例足月分娩,获得6名无先天性畸形的婴儿。6名儿童出生后生长发育正常。所有女性均未发生继发肿瘤。
EP方案治疗高危、化疗耐药及复发性GTN有效且安全。